402 related articles for article (PubMed ID: 14532780)
21. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
Adolfsson J; Tribukait B; Levitt S
Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
[TBL] [Abstract][Full Text] [Related]
22. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor.
Cooperberg MR; Lubeck DP; Grossfeld GD; Mehta SS; Carroll PR
J Urol; 2002 Aug; 168(2):491-5. PubMed ID: 12131295
[TBL] [Abstract][Full Text] [Related]
23. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
Konety BR; Bird VY; Deorah S; Dahmoush L
J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287
[TBL] [Abstract][Full Text] [Related]
25. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening.
Yan Y; Carvalhal GF; Catalona WJ; Young JD
Cancer; 2000 Mar; 88(5):1122-30. PubMed ID: 10699903
[TBL] [Abstract][Full Text] [Related]
26. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
27. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.
Ercole B; Marietti SR; Fine J; Albertsen PC
J Urol; 2008 Oct; 180(4):1336-9; discussion 1340-1. PubMed ID: 18707696
[TBL] [Abstract][Full Text] [Related]
28. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE.
Meng MV; Elkin EP; Harlan SR; Mehta SS; Lubeck DP; Carroll PR
J Urol; 2003 Dec; 170(6 Pt 1):2279-83. PubMed ID: 14634396
[TBL] [Abstract][Full Text] [Related]
29. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
Leibovici D; Lindner A; Stay K; Zisman A
Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
[TBL] [Abstract][Full Text] [Related]
30. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
[TBL] [Abstract][Full Text] [Related]
31. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease.
Dall'era MA; Hosang N; Konety B; Cowan JE; Carroll PR
J Urol; 2009 Apr; 181(4):1622-7; discussion 1627. PubMed ID: 19230923
[TBL] [Abstract][Full Text] [Related]
32. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
[TBL] [Abstract][Full Text] [Related]
33. Predictors of fatigue after treatment for prostate cancer.
Maliski SL; Kwan L; Orecklin JR; Saigal CS; Litwin MS
Urology; 2005 Jan; 65(1):101-8. PubMed ID: 15667873
[TBL] [Abstract][Full Text] [Related]
34. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.
Latini DM; Hart SL; Knight SJ; Cowan JE; Ross PL; Duchane J; Carroll PR;
J Urol; 2007 Sep; 178(3 Pt 1):826-31; discussion 831-2. PubMed ID: 17632144
[TBL] [Abstract][Full Text] [Related]
35. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
[TBL] [Abstract][Full Text] [Related]
37. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
38. The independent impact of extended pattern biopsy on prostate cancer stage migration.
Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
Macdonald OK; D'Amico AV; Sadetsky N; Shrieve DC; Carroll PR
Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
[TBL] [Abstract][Full Text] [Related]
40. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE.
Litwin MS; Sadetsky N; Pasta DJ; Lubeck DP
J Urol; 2004 Aug; 172(2):515-9. PubMed ID: 15247718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
